Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 241

1.

Selective progesterone receptor modulators in early stage breast cancer: a randomized, placebo-controlled Phase II window of opportunity trial using telapristone acetate.

Lee O, Sullivan ME, Xu Y, Rodgers C, Muzzio M, Helenowski I, Shidfar A, Zeng Z, Singhal H, Jovanovic B, Hansen N, Bethke KP, Gann PH, Gradishar W, Kim JJ, Clare SE, Khan SA.

Clin Cancer Res. 2019 Sep 30. pii: clincanres.0443.2019. doi: 10.1158/1078-0432.CCR-19-0443. [Epub ahead of print]

PMID:
31570566
2.

Current state of clinical trials in breast cancer brain metastases.

Fares J, Kanojia D, Cordero A, Rashidi A, Miska J, Schwartz CW, Savchuk S, Ahmed AU, Balyasnikova IV, Cristofanilli M, Gradishar WJ, Lesniak MS.

Neurooncol Pract. 2019 Sep;6(5):392-401. doi: 10.1093/nop/npz003. Epub 2019 Feb 11.

PMID:
31555454
3.

Are Biosimilars the Future of Oncology and Haematology?

Zinzani PL, Dreyling M, Gradishar W, Andre M, Esteva FJ, Boulos S, González Barca E, Curigliano G.

Drugs. 2019 Oct;79(15):1609-1624. doi: 10.1007/s40265-019-01193-y.

PMID:
31541401
4.

Feasibility and acceptability of intensive longitudinal data collection of activity and patient-reported outcomes during chemotherapy for breast cancer.

Solk P, Gavin K, Fanning J, Welch W, Lloyd G, Cottrell A, Nielsen A, Santa Maria CA, Gradishar W, Khan SA, Kulkarni S, Siddique J, Phillips SM.

Qual Life Res. 2019 Sep 6. doi: 10.1007/s11136-019-02278-7. [Epub ahead of print]

PMID:
31493269
5.

NCCN Guidelines Updates: Breast Cancer.

Telli ML, Gradishar WJ, Ward JH.

J Natl Compr Canc Netw. 2019 May 1;17(5.5):552-555. doi: 10.6004/jnccn.2019.5006.

PMID:
31117035
6.

A novel small-molecule antagonizes PRMT5-mediated KLF4 methylation for targeted therapy.

Zhou Z, Feng Z, Hu D, Yang P, Gur M, Bahar I, Cristofanilli M, Gradishar WJ, Xie XQ, Wan Y.

EBioMedicine. 2019 Jun;44:98-111. doi: 10.1016/j.ebiom.2019.05.011. Epub 2019 May 14.

7.

Prognostic role of serum thymidine kinase 1 activity in patients with hormone receptor-positive metastatic breast cancer: Analysis of the randomised phase III Evaluation of Faslodex versus Exemestane Clinical Trial (EFECT).

McCartney A, Biagioni C, Schiavon G, Bergqvist M, Mattsson K, Migliaccio I, Benelli M, Romagnoli D, Bonechi M, Boccalini G, Pestrin M, Galardi F, De Luca F, Biganzoli L, Piccart M, Gradishar WJ, Chia S, Di Leo A, Malorni L.

Eur J Cancer. 2019 Jun;114:55-66. doi: 10.1016/j.ejca.2019.04.002. Epub 2019 May 3.

PMID:
31059974
8.

U.S. prevalence of endocrine therapy-naïve locally advanced or metastatic breast cancer.

Nunes AP, Liang C, Gradishar WJ, Dalvi T, Lewis J, Jones N, Green E, Doherty M, Seeger JD.

Curr Oncol. 2019 Apr;26(2):e180-e187. doi: 10.3747/co.26.4163. Epub 2019 Apr 1.

9.

Prediction of chemotherapy benefit by EndoPredict in patients with breast cancer who received adjuvant endocrine therapy plus chemotherapy or endocrine therapy alone.

Sestak I, Martín M, Dubsky P, Kronenwett R, Rojo F, Cuzick J, Filipits M, Ruiz A, Gradishar W, Soliman H, Schwartzberg L, Buus R, Hlauschek D, Rodríguez-Lescure A, Gnant M.

Breast Cancer Res Treat. 2019 Jul;176(2):377-386. doi: 10.1007/s10549-019-05226-8. Epub 2019 Apr 30.

10.

Relationship of pathological features and a 21 gene expression assay in younger versus older women with node-negative endocrine receptor-positive breast cancer.

Mutonga M, Speedy S, Rademaker A, Liu D, Uthe R, Jain S, Gradishar WJ, Flaum L, Santa-Maria CA.

Breast Cancer Res Treat. 2019 Jul;176(1):95-100. doi: 10.1007/s10549-018-05088-6. Epub 2019 Apr 11.

PMID:
30977026
11.

NCCN Guidelines Insights: Breast Cancer, Version 3.2018.

Goetz MP, Gradishar WJ, Anderson BO, Abraham J, Aft R, Allison KH, Blair SL, Burstein HJ, Dang C, Elias AD, Farrar WB, Giordano SH, Goldstein LJ, Isakoff SJ, Lyons J, Marcom PK, Mayer IA, Moran MS, Mortimer J, O'Regan RM, Patel SA, Pierce LJ, Reed EC, Rugo HS, Sitapati A, Smith KL, Smith ML, Soliman H, Telli ML, Ward JH, Young JS, Shead DA, Kumar R.

J Natl Compr Canc Netw. 2019 Feb;17(2):118-126. doi: 10.6004/jnccn.2019.0009.

PMID:
30787125
12.

Innovating Cancer Care Delivery: the Example of the 4R Oncology Model for Colorectal Cancer Patients.

Trosman J, Weldon C, Kircher S, Gradishar W, Benson A 3rd.

Curr Treat Options Oncol. 2019 Feb 11;20(2):11. doi: 10.1007/s11864-019-0608-7. Review.

PMID:
30741356
13.

The National Physicians Cooperative: transforming fertility management in the cancer setting and beyond.

Smith BM, Duncan FE, Ataman L, Smith K, Quinn GP, Chang RJ, Finlayson C, Orwig K, Valli-Pulaski H, Moravek MB, Zelinski MB, Irene Su H, Vitek W, Smith JF, Jeruss JS, Gracia C, Coutifaris C, Shah D, Nahata L, Gomez-Lobo V, Appiah LC, Brannigan RE, Gillis V, Gradishar W, Javed A, Rhoton-Vlasak AS, Kondapalli LA, Neuber E, Ginsberg JP, Muller CH, Hirshfeld-Cytron J, Kutteh WH, Lindheim SR, Cherven B, Meacham LR, Rao P, Torno L, Sender LS, Vadaparampil ST, Skiles JL, Schafer-Kalkhoff T, Frias OJ, Byrne J, Westphal LM, Schust DJ, Klosky JL, McCracken KA, Ting A, Khan Z, Granberg C, Lockart B, Scoccia B, Laronda MM, Mersereau JE, Marsh C, Pavone ME, Woodruff TK.

Future Oncol. 2018 Dec;14(29):3059-3072. doi: 10.2217/fon-2018-0278. Epub 2018 Nov 26.

14.

From the Past to the Present: Insurer Coverage Frameworks for Next-Generation Tumor Sequencing.

Trosman JR, Weldon CB, Gradishar WJ, Benson AB 3rd, Cristofanilli M, Kurian AW, Ford JM, Balch A, Watkins J, Phillips KA.

Value Health. 2018 Sep;21(9):1062-1068. doi: 10.1016/j.jval.2018.06.011. Epub 2018 Aug 3.

15.

Adjuvant Anthracyclines in Breast Cancer: What Is Their Role?

Shah AN, Gradishar WJ.

Oncologist. 2018 Oct;23(10):1153-1161. doi: 10.1634/theoncologist.2017-0672. Epub 2018 Aug 17. Review.

16.

Double-Blind Phase III Trial of Adjuvant Chemotherapy With and Without Bevacizumab in Patients With Lymph Node-Positive and High-Risk Lymph Node-Negative Breast Cancer (E5103).

Miller KD, O'Neill A, Gradishar W, Hobday TJ, Goldstein LJ, Mayer IA, Bloom S, Brufsky AM, Tevaarwerk AJ, Sparano JA, Le-Lindqwister NA, Hendricks CB, Northfelt DW, Dang CT, Sledge GW Jr.

J Clin Oncol. 2018 Sep 1;36(25):2621-2629. doi: 10.1200/JCO.2018.79.2028. Epub 2018 Jul 24.

17.

Phase I study of alpelisib (BYL-719) and trastuzumab emtansine (T-DM1) in HER2-positive metastatic breast cancer (MBC) after trastuzumab and taxane therapy.

Jain S, Shah AN, Santa-Maria CA, Siziopikou K, Rademaker A, Helenowski I, Cristofanilli M, Gradishar WJ.

Breast Cancer Res Treat. 2018 Sep;171(2):371-381. doi: 10.1007/s10549-018-4792-0. Epub 2018 May 30.

PMID:
29850984
18.

NCCN Guidelines Updates: Breast Cancer.

Giordano SH, Elias AD, Gradishar WJ.

J Natl Compr Canc Netw. 2018 May;16(5S):605-610. doi: 10.6004/jnccn.2018.0043.

PMID:
29784737
19.

A pilot study of durvalumab and tremelimumab and immunogenomic dynamics in metastatic breast cancer.

Santa-Maria CA, Kato T, Park JH, Kiyotani K, Rademaker A, Shah AN, Gross L, Blanco LZ, Jain S, Flaum L, Tellez C, Stein R, Uthe R, Gradishar WJ, Cristofanilli M, Nakamura Y, Giles FJ.

Oncotarget. 2018 Apr 10;9(27):18985-18996. doi: 10.18632/oncotarget.24867. eCollection 2018 Apr 10.

20.

Risk factors for the development of paclitaxel-induced neuropathy in breast cancer patients.

Robertson J, Raizer J, Hodges JS, Gradishar W, Allen JA.

J Peripher Nerv Syst. 2018 Jun;23(2):129-133. doi: 10.1111/jns.12271. Epub 2018 May 11.

PMID:
29696771
21.

Everolimus Plus Endocrine Therapy for Postmenopausal Women With Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: A Clinical Trial.

Royce M, Bachelot T, Villanueva C, Özgüroglu M, Azevedo SJ, Cruz FM, Debled M, Hegg R, Toyama T, Falkson C, Jeong J, Srimuninnimit V, Gradishar WJ, Arce C, Ridolfi A, Lin C, Cardoso F.

JAMA Oncol. 2018 Jul 1;4(7):977-984. doi: 10.1001/jamaoncol.2018.0060.

22.

Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology.

Gradishar WJ, Anderson BO, Balassanian R, Blair SL, Burstein HJ, Cyr A, Elias AD, Farrar WB, Forero A, Giordano SH, Goetz MP, Goldstein LJ, Isakoff SJ, Lyons J, Marcom PK, Mayer IA, McCormick B, Moran MS, O'Regan RM, Patel SA, Pierce LJ, Reed EC, Salerno KE, Schwartzberg LS, Sitapati A, Smith KL, Smith ML, Soliman H, Somlo G, Telli ML, Ward JH, Kumar R, Shead DA.

J Natl Compr Canc Netw. 2018 Mar;16(3):310-320. doi: 10.6004/jnccn.2018.0012.

PMID:
29523670
23.

Targeting the PI3K/AKT/mTOR pathway in triple-negative breast cancer: a review.

Costa RLB, Han HS, Gradishar WJ.

Breast Cancer Res Treat. 2018 Jun;169(3):397-406. doi: 10.1007/s10549-018-4697-y. Epub 2018 Feb 7. Review.

PMID:
29417298
24.

Do Genomic Assays Provide the Necessary Confidence to De-escalate Adjuvant Therapy?

Costa RLB, Gradishar WJ.

J Clin Oncol. 2018 Mar 10;36(8):725-727. doi: 10.1200/JCO.2017.76.9802. Epub 2018 Jan 26. No abstract available.

PMID:
29373092
25.

Enzalutamide for the Treatment of Androgen Receptor-Expressing Triple-Negative Breast Cancer.

Traina TA, Miller K, Yardley DA, Eakle J, Schwartzberg LS, O'Shaughnessy J, Gradishar W, Schmid P, Winer E, Kelly C, Nanda R, Gucalp A, Awada A, Garcia-Estevez L, Trudeau ME, Steinberg J, Uppal H, Tudor IC, Peterson A, Cortes J.

J Clin Oncol. 2018 Mar 20;36(9):884-890. doi: 10.1200/JCO.2016.71.3495. Epub 2018 Jan 26.

26.

Advances in Endocrine Therapy for Postmenopausal Metastatic Breast Cancer.

Flaum LE, Gradishar WJ.

Cancer Treat Res. 2018;173:141-154. doi: 10.1007/978-3-319-70197-4_9. Review.

PMID:
29349762
27.

Long-term outcomes in cancer patients who did or did not pursue fertility preservation.

Moravek MB, Confino R, Smith KN, Kazer RR, Klock SC, Lawson AK, Gradishar WJ, Pavone ME.

Fertil Steril. 2018 Feb;109(2):349-355. doi: 10.1016/j.fertnstert.2017.10.029. Epub 2018 Jan 17.

28.

Phase III, Randomized Study of Dual Human Epidermal Growth Factor Receptor 2 (HER2) Blockade With Lapatinib Plus Trastuzumab in Combination With an Aromatase Inhibitor in Postmenopausal Women With HER2-Positive, Hormone Receptor-Positive Metastatic Breast Cancer: ALTERNATIVE.

Johnston SRD, Hegg R, Im SA, Park IH, Burdaeva O, Kurteva G, Press MF, Tjulandin S, Iwata H, Simon SD, Kenny S, Sarp S, Izquierdo MA, Williams LS, Gradishar WJ.

J Clin Oncol. 2018 Mar 10;36(8):741-748. doi: 10.1200/JCO.2017.74.7824. Epub 2017 Dec 15.

PMID:
29244528
29.

Cell-Free DNA and Circulating Tumor Cells: Comprehensive Liquid Biopsy Analysis in Advanced Breast Cancer.

Rossi G, Mu Z, Rademaker AW, Austin LK, Strickland KS, Costa RLB, Nagy RJ, Zagonel V, Taxter TJ, Behdad A, Wehbe FH, Platanias LC, Gradishar WJ, Cristofanilli M.

Clin Cancer Res. 2018 Feb 1;24(3):560-568. doi: 10.1158/1078-0432.CCR-17-2092. Epub 2017 Nov 27.

30.

Veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in patients with BRCA1/2 locally recurrent/metastatic breast cancer: randomized phase II study.

Han HS, Diéras V, Robson M, Palácová M, Marcom PK, Jager A, Bondarenko I, Citrin D, Campone M, Telli ML, Domchek SM, Friedlander M, Kaufman B, Garber JE, Shparyk Y, Chmielowska E, Jakobsen EH, Kaklamani V, Gradishar W, Ratajczak CK, Nickner C, Qin Q, Qian J, Shepherd SP, Isakoff SJ, Puhalla S.

Ann Oncol. 2018 Jan 1;29(1):154-161. doi: 10.1093/annonc/mdx505.

31.

Analyses of selected safety endpoints in phase 1 and late-phase clinical trials of anti-PD-1 and PD-L1 inhibitors: prediction of immune-related toxicities.

Costa R, Costa RB, Talamantes SM, Helenoswki I, Carneiro BA, Chae YK, Gradishar WJ, Kurzrock R, Giles FJ.

Oncotarget. 2017 Jun 29;8(40):67782-67789. doi: 10.18632/oncotarget.18847. eCollection 2017 Sep 15.

32.

In Reply.

Gradishar W, Brown K, Mundt E, Manley S.

Oncologist. 2017 Dec;22(12):1540. doi: 10.1634/theoncologist.2017-0320. Epub 2017 Aug 29. No abstract available.

33.

Differences Are Important: Breast Cancer Therapy in Different Ethnic Groups.

Costa RLB, Gradishar WJ.

J Glob Oncol. 2017 Apr 11;3(4):281-284. doi: 10.1200/JGO.2017.009936. eCollection 2017 Aug. No abstract available.

34.

RESILIENCE: Phase III Randomized, Double-Blind Trial Comparing Sorafenib With Capecitabine Versus Placebo With Capecitabine in Locally Advanced or Metastatic HER2-Negative Breast Cancer.

Baselga J, Zamagni C, Gómez P, Bermejo B, Nagai SE, Melichar B, Chan A, Mángel L, Bergh J, Costa F, Gómez HL, Gradishar WJ, Hudis CA, Rapoport BL, Roché H, Maeda P, Huang L, Meinhardt G, Zhang J, Schwartzberg LS.

Clin Breast Cancer. 2017 Dec;17(8):585-594.e4. doi: 10.1016/j.clbc.2017.05.006. Epub 2017 May 22.

35.

A pilot study of cabergoline for the treatment of metastatic breast cancer.

Costa R, Santa-Maria CA, Scholtens DM, Jain S, Flaum L, Gradishar WJ, Clevenger CV, Kaklamani VG.

Breast Cancer Res Treat. 2017 Oct;165(3):585-592. doi: 10.1007/s10549-017-4370-x. Epub 2017 Jul 3.

PMID:
28674764
36.

Meta-analysis of selected toxicity endpoints of CDK4/6 inhibitors: Palbociclib and ribociclib.

Costa R, Costa RB, Talamantes SM, Helenowski I, Peterson J, Kaplan J, Carneiro BA, Giles FJ, Gradishar WJ.

Breast. 2017 Oct;35:1-7. doi: 10.1016/j.breast.2017.05.016. Epub 2017 Jun 12. Review.

PMID:
28618307
37.

New Approaches to Endocrine Therapy for Breast Cancer.

Gradishar WJ.

J Natl Compr Canc Netw. 2017 May;15(5S):679-681.

PMID:
28515242
38.

Triple-Negative Breast Cancer: Current Practice and Future Directions.

Costa RLB, Gradishar WJ.

J Oncol Pract. 2017 May;13(5):301-303. doi: 10.1200/JOP.2017.023333. No abstract available.

PMID:
28489982
39.

Concordance of Genomic Alterations by Next-Generation Sequencing in Tumor Tissue versus Circulating Tumor DNA in Breast Cancer.

Chae YK, Davis AA, Jain S, Santa-Maria C, Flaum L, Beaubier N, Platanias LC, Gradishar W, Giles FJ, Cristofanilli M.

Mol Cancer Ther. 2017 Jul;16(7):1412-1420. doi: 10.1158/1535-7163.MCT-17-0061. Epub 2017 Apr 26.

40.

Clinical Variant Classification: A Comparison of Public Databases and a Commercial Testing Laboratory.

Gradishar W, Johnson K, Brown K, Mundt E, Manley S.

Oncologist. 2017 Jul;22(7):797-803. doi: 10.1634/theoncologist.2016-0431. Epub 2017 Apr 13.

41.

NCCN Guidelines Insights: Breast Cancer, Version 1.2017.

Gradishar WJ, Anderson BO, Balassanian R, Blair SL, Burstein HJ, Cyr A, Elias AD, Farrar WB, Forero A, Giordano SH, Goetz MP, Goldstein LJ, Isakoff SJ, Lyons J, Marcom PK, Mayer IA, McCormick B, Moran MS, O'Regan RM, Patel SA, Pierce LJ, Reed EC, Salerno KE, Schwartzberg LS, Sitapati A, Smith KL, Smith ML, Soliman H, Somlo G, Telli M, Ward JH, Shead DA, Kumar R.

J Natl Compr Canc Netw. 2017 Apr;15(4):433-451.

PMID:
28404755
42.

Endocrine Therapy in the Current Management of Postmenopausal Estrogen Receptor-Positive Metastatic Breast Cancer.

Kaklamani VG, Gradishar WJ.

Oncologist. 2017 May;22(5):507-517. doi: 10.1634/theoncologist.2015-0464. Epub 2017 Mar 17. Review.

43.

Systematic analysis of early phase clinical studies for patients with breast cancer: Inclusion of patients with brain metastasis.

Costa R, Gill N, Rademaker AW, Carneiro BA, Chae YK, Kumthekar P, Gradishar WJ, Kurzrock R, Giles FJ.

Cancer Treat Rev. 2017 Apr;55:10-15. doi: 10.1016/j.ctrv.2017.02.006. Epub 2017 Feb 22. Review.

PMID:
28279895
44.

Randomized Phase II Study of Ramucirumab or Icrucumab in Combination with Capecitabine in Patients with Previously Treated Locally Advanced or Metastatic Breast Cancer.

Vahdat LT, Layman R, Yardley DA, Gradishar W, Salkeni MA, Joy AA, Garcia AA, Ward P, Khatcheressian J, Sparano J, Rodriguez G, Tang S, Gao L, Dalal RP, Kauh J, Miller K.

Oncologist. 2017 Mar;22(3):245-254. doi: 10.1634/theoncologist.2016-0265. Epub 2017 Feb 20.

45.

Breast Cancer Outcomes After Diagnosis of Hormone-positive Breast Cancer and Subsequent Pregnancy in the Tamoxifen Era.

Nye L, Rademaker A, Gradishar WJ.

Clin Breast Cancer. 2017 Jul;17(4):e185-e189. doi: 10.1016/j.clbc.2016.12.014. Epub 2017 Jan 9.

46.

Developmental therapeutics for patients with breast cancer and central nervous system metastasis: current landscape and future perspectives.

Costa R, Carneiro BA, Wainwright DA, Santa-Maria CA, Kumthekar P, Chae YK, Gradishar WJ, Cristofanilli M, Giles FJ.

Ann Oncol. 2017 Jan 1;28(1):44-56. doi: 10.1093/annonc/mdw532. Review.

PMID:
28177431
47.

Continued Treatment Effect of Zoledronic Acid Dosing Every 12 vs 4 Weeks in Women With Breast Cancer Metastatic to Bone: The OPTIMIZE-2 Randomized Clinical Trial.

Hortobagyi GN, Van Poznak C, Harker WG, Gradishar WJ, Chew H, Dakhil SR, Haley BB, Sauter N, Mohanlal R, Zheng M, Lipton A.

JAMA Oncol. 2017 Jul 1;3(7):906-912. doi: 10.1001/jamaoncol.2016.6316.

48.

Targeting Epidermal Growth Factor Receptor in triple negative breast cancer: New discoveries and practical insights for drug development.

Costa R, Shah AN, Santa-Maria CA, Cruz MR, Mahalingam D, Carneiro BA, Chae YK, Cristofanilli M, Gradishar WJ, Giles FJ.

Cancer Treat Rev. 2017 Feb;53:111-119. doi: 10.1016/j.ctrv.2016.12.010. Epub 2017 Jan 5. Review.

PMID:
28104566
49.

Breast cancer: updates and advances in 2016.

Giordano SB, Gradishar W.

Curr Opin Obstet Gynecol. 2017 Feb;29(1):12-17. doi: 10.1097/GCO.0000000000000343. Review.

PMID:
27977463
50.

Developmental therapeutics for inflammatory breast cancer: Biology and translational directions.

Costa R, Santa-Maria CA, Rossi G, Carneiro BA, Chae YK, Gradishar WJ, Giles FJ, Cristofanilli M.

Oncotarget. 2017 Feb 14;8(7):12417-12432. doi: 10.18632/oncotarget.13778. Review.

Supplemental Content

Loading ...
Support Center